Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 3810
118th Congress(2023-2024)
Drug Origin Transparency Act of 2023
Introduced
Introduced
Introduced in House on Jun 5, 2023
Overview
Text
Introduced in House 
Jun 5, 2023
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Jun 5, 2023)
Jun 5, 2023
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 3810 (Introduced-in-House)


118th CONGRESS
1st Session
H. R. 3810


To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

June 5, 2023

Ms. Eshoo introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Drug Origin Transparency Act of 2023”.

SEC. 2. Enhanced drug manufacturing amount information reporting.

(a) In general.—Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended—

(1) in subparagraph (A), by adding “or (2)” after “paragraph (1)”; and

(2) by adding at the end the following:

“(C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall—

“(i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as—

“(I) the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and

“(II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material from each such identified supplier; and

“(ii) be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year.

“(D) Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).”.

(b) Conforming amendment.—Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 510(j)(3)(B)) is amended by striking “subparagraph (A)” and inserting “this paragraph”.

SEC. 3. Require drug labeling to include original manufacturer and supply chain information.

Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended—

(1) in paragraph (b)—

(A) by striking “(b) If in a package” and inserting “(b)(1) If in a package”;

(B) by striking “a label containing (1) the name and place” and inserting “a label containing—

“(A) the name and place”;

(C) by striking “or distributor; and (2) an accurate statement” and inserting “or distributor; and

“(B) an accurate statement”;

(D) by striking “under clause (2) of this paragraph” and inserting “under this clause”; and

(E) by inserting at the end the following:

“(2) (A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements.

“(B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient.

“(C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.”; and

(2) by inserting after paragraph (c) the following:

“(d) (1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of—

“(A) the original manufacturer of each active pharmaceutical ingredient;

“(B) each manufacturer, if different from the original manufacturer; and

“(C) the packer or distributor, if any.

“(2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.”.